Ampio Pharmaceuticals, Inc

Regulus Pharmaceutical Consulting Inc. is a business management consultant that caters to the pharmaceutical, biotechnology and dietary supplement markets. Based in Boulder, Colo., the firm offers guidance in laboratory quality issues, quality management systems, routine monitoring, Good Manufacturing Practice (GMP) audits and quality control (QC) procedures. In addition, it performs Good Clinical Practice (GCP) audits of clinical protocols, investigator sites, master files, pharmacovigilance, databases and reports. The company caters to pharmaceutical and biotechnology clients in the manufacturing, nonclinical, clinical, regulatory affairs, project management and medical/technical writing areas.

Msbiotec is a biotechnology company based in Greenwood Village, CO. Specializing in research and development, the company focuses on creating innovative solutions in the field of biotechnology. With a team of dedicated scientists and experts, Msbiotec is committed to advancing scientific knowledge and pushing the boundaries of biotechnological advancements. The company's work encompasses a wide range of applications, contributing to the growth and evolution of the biotechnology industry. Generated from their business information

ARCA Biopharma is a late-stage biopharmaceutical company based in Westminster, CO, specializing in tailored healthcare and pharmacogenetic precision medicine for cardiovascular disease, particularly atrial fibrillation. They aim to address the unmet medical need for safe and effective drug therapies for patients with atrial fibrillation and heart failure, utilizing their potentially groundbreaking genetically-targeted AF treatment, Gencaro. With a focus on precision medicine, ARCA Biopharma recognizes that individual patients respond differently to their disease and treatment, and they strive to develop personalized medical treatments based on the unique characteristics of each patient. Their research and clinical trials, such as the rNAPc2 AB201 clinical trial, aim to improve the success rate of common drug therapies, which currently only have a success rate of 1/3 to 2/3. As cardiovascular disease remains the leading cause of death in the United States, ARCA Biopharma's innovative approach holds promise in revolutionizing the treatment of atrial fibrillation and improving patient outcomes.Generated from the website